Revenue
2016
2017
2018
2019
2020
2022
2023
2024
2025
ENDRA Life Sciences Inc. (NDRA)
Price$6.16Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | $0 | $0 | $6,174 | $351,622 | $515,582 |
| Gross profit | — | — | — | — | $0 | $0 | $0 | $6,174 | $178,840 | $279,704 |
| Gross margin | — | — | — | — | — | — | — | 100.00% | 50.86% | 54.25% |
| Research & development | $1.8M | $3.2M | $5.0M | $6.6M | $5.5M | $5.9M | $6.6M | $4.7M | $1.9M | $495,377 |
| Operating expenses | $5.8M | $10.8M | $10.5M | $13.2M | $11.5M | $11.5M | $10.8M | $9.0M | $4.8M | $2.1M |
| Operating income | −$5.8M | −$10.8M | −$10.5M | −$13.2M | −$11.5M | −$11.5M | −$10.8M | −$9.0M | −$4.6M | −$1.8M |
| Operating margin | — | — | — | — | — | — | — | −146,080.47% | −1,315.63% | −347.52% |
| EBITDA | −$5.7M | −$10.8M | −$10.4M | −$13.1M | −$11.4M | −$11.4M | −$10.8M | −$9.0M | −$4.6M | −$1.7M |
| EBITDA margin | — | — | — | — | — | — | — | −144,973.96% | −1,298.15% | −334.93% |
| Net income | −$7.0M | −$11.5M | −$10.1M | −$13.2M | −$11.2M | −$11.7M | −$13.3M | −$9.8M | −$5.4M | −$2.8M |
| Net profit margin | — | — | — | — | — | — | — | −158,669.60% | −1,529.19% | −538.30% |
| Basic EPSper basic share | -$8.93 | -$56.94 | -$1.58 | -$4.56 | -$5.55 | -$12.60 | -$46.80 | -$43.40 | -$39.00 | -$76.80 |
| Diluted EPSper diluted share | -$8.93 | -$56.94 | -$2,766.85 | -$4.56 | — | -$12.60 | -$46.80 | -$43.40 | -$39.00 | -$76.80 |
Owners
Reported shareholders
≈9.11%of listed shares
DIGIANDOMENICO ANTHONY136.59K shares · Jan 21, 2026
View holders
| Holder | % owned |
|---|---|
DIGIANDOMENICO ANTHONY | ≈9.11%136.59K shares |
Tokman Alexander Y | ≈6.80%101.93K shares |
Harsh Michael | ≈4.38%65.71K shares |
Basenese Lou | ≈4.38%65.71K shares |
Altium Capital Management LLC | 3.95%59.27K shares |
Jacroux Richard | ≈2.23%33.46K shares |
CITADEL ADVISORS LLC | 2.00%29.92K shares |
CITIZENS FINANCIAL GROUP INC/RI | 1.89%28.4K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.99%14.91K shares |
VANGUARD FIDUCIARY TRUST CO | 0.67%10.12K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.49%7.34K shares |
MORGAN STANLEY | 0.24%3.55K shares |
UBS Group AG | <0.01%68 shares |
Tower Research Capital LLC (TRC) | <0.01%58 shares |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | <0.01%19 shares |
Percentages use 1.5M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 27, 2024Form 4/A | UBS Group AGOther | BuyCommon Stock · indirect | 0 | $0.00 | $0.00 | 146.0K |
| Aug 27, 2024Form 4 | UBS Group AGTenPercentOwner | BuyCommon Stock · indirect | 3.7K | $0.55 | $2.0K | 146.0K |